

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/744,007	12/24/2003	Tetsuo Nagano	P24350	9418
7055	7590 03/22/2006		EXAMINER	
GREENBLUM & BERNSTEIN, P.L.C.			CROSS, LATOYA I	
	1950 ROLAND CLARKE PLACE RESTON, VA 20191		ART UNIT	PAPER NUMBER
,			1743	

DATE MAILED: 03/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

			,			
	Application No.	Applicant(s)				
	10/744,007	NAGANO ET AL.				
Office Action Summary	Examiner	Art Unit				
	LaToya C. Younger	1743				
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with	the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REL WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the may be arrived patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICA 1.136(a). In no event, however, may a reply od will apply and will expire SIX (6) MONTH: tute, cause the application to become ABAN	TION. be timely filed from the mailing date of this communication. DONED (35 U.S.C. § 133).				
Status	•					
1) Responsive to communication(s) filed on 24	1 December 2003.					
2a)☐ This action is FINAL . 2b)⊠ T	This action is FINAL . 2b) This action is non-final.					
3) Since this application is in condition for allow	wance except for formal matters	, prosecution as to the merits is				
closed in accordance with the practice unde	er <i>Ex parte Quayle</i> , 1935 C.D. 1	1, 453 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 9-14 is/are pending in the applicating 4a) Of the above claim(s) is/are with description 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 9-14 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	rawn from consideration.					
Application Papers			٠			
9)☐ The specification is objected to by the Exam	iner.					
10) The drawing(s) filed on is/are: a) a	•					
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the corr 11) The oath or declaration is objected to by the		,				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreignable. a) All b) Some * c) None of: 1. Certified copies of the priority documents. 2. Certified copies of the priority documents. 3. Copies of the certified copies of the priority documents. * See the attached detailed Office action for a limit of the priority.	ents have been received. ents have been received in App riority documents have been receau (PCT Rule 17.2(a)).	ication No ceived in this National Stage				
Attachment(s)	 □	(270.140)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 3/24/04. 		mary (PTO-413) ail Date mal Patent Application (PTO-152)				

Page 2

DETAILED ACTION

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 9-14 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 6,756,231 in view of US patent 6,201,134 to Nagano et al. The compounds of the instant invention are essentially structural isomers of those already patented in the '134 patent. The compounds differ only in the presence of a lactone group instead of the – COO- group found in the '134 patent. Nagano et al teach that that rhodamine derivatives may form a lactone ring and exist as compounds in a free form (col. 9, lines 38-40). Therefore, the compounds of the instant invention are obvious variants of those claimed in the '134 patent.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claims 9-14 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 99/01447 to Nagano et al, having a publication date of January 14, 1999 (US equivalent, 6,201,134 used as a translated version of the WO publication).

Nagano et al teach diamino-rhodamine derivatives having the structural formula (I)' shown in column 10 of the reference:

$$R^{10}$$
 R^{10}
 R^{10}

In the formula, R1 and R2 represent amino groups present at adjacent positions. R7, R8, R9 and R10 represent a hydrogen atom, the same as present in the instantly claimed compound. R3, R4, R5 and R6 represent a C1-C6 alkyl group as recited in claim 10. With respect to claim 11, Nagano et al teach that the compounds are useful as reagents for nitric oxide detection (see abstract).

Nagano et al further teach compounds having the structural formulas (II)' also shown in column 10 of the reference:

Application/Control Number: 10/744,007

Art Unit: 1743

In the formula, R21 and R22 represent amino groups present at adjacent positions that bind to each other to form a group represented as –N=N-NR- that forms a ring (col. 10, lines 41-48). R27, R28, R29 and R30 represent a hydrogen atom, the same as present in the instantly claimed compound. R23, R24, R25 and R26 represent a C1-C6 alkyl group as recited in claim 13. With respect to claim 14, Nagano et al teach that nitric oxide measurement takes place by allowing the compound of formula (I)' to react with nitric oxide to form a compound of formula (II)', followed by measuring the fluorescence of the compound of formula (II)'. See col. 10, line 66 – col. 11, line 5.

Therefore, for the reasons set forth above, Applicants' claimed invention is deemed to be anticipated within the meaning of 35 USC 102(b) in view of the teachings of Nagano et al.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to LaToya C. Younger whose telephone number is 571-272-1256. The examiner can normally be reached on Monday-Thursday 10:30 a.m. - 7:00 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jill A. Warden can be reached on 571-272-1267. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1743

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

lcy